Breakthrough Victoria invests $800,000 in Melbourne’s Diag-Nose.io to advance respiratory health

Breakthrough Victoria has invested $800,000 in Diag-Nose.io Medical (DNM), a Melbourne-based innovator in respiratory healthcare, to enhance clinical management and drug discovery for chronic respiratory diseases globally.

Originally launched from Stanford’s ENT Innovation Program and now headquartered in Notting Hill, Melbourne, Diag-Nose.io is revolutionising the treatment of chronic respiratory diseases (CRDs) like asthma and COPD, which affect over 450 million people worldwide. Their cutting-edge product, RhinoMAP, utilises proprietary protein chemistry and AI to rapidly and accurately map biological subtypes of respiratory disorders. This breakthrough technology enables more precise treatment, reducing healthcare costs and improving patient outcomes.

RhinoMAP’s AI-powered analytics platform works by analysing data from a patented nasal liquid biopsy device, helping medical professionals assess disease progression and treatment responsiveness efficiently. This is a significant advancement over traditional methods that often rely on less precise data, leading to a trial-and-error approach in treatment that can result in poor compliance and adverse events.

Lauren Morrey, Acting-CEO of Breakthrough Victoria, commented on the investment, “Our investment in Diag-Nose.io reflects our commitment to supporting groundbreaking technologies that could make a profound difference to patient outcomes and streamline drug development.

“By enabling faster and more accurate treatment decisions, their pioneering RhinoMAP platform can make a profound impact on millions of lives affected by chronic respiratory conditions worldwide.”

Minister for Economic Growth, Danny Pearson, also supported the investment, stating, “This investment not only creates high value jobs here in Victoria, it drives economic growth and strengthens our reputation as a global leader in medtech.”

DNM’s CEO, Eldin Rostom, expressed his vision for the future, “Together with the new biologics medicines, our RhinoMAP platform will bring us one step closer towards the holy grail of respiratory medicine; helping patients become completely free of symptoms. This progress is only made possible thanks to the dedicated support and investment from visionary partners like Breakthrough Victoria.”

Picture: the DNM team (credit Breakthrough Victoria)

Further Reading

Cyclopharm makes first sale to giant US healthcare system

Baxter Healthcare pharmaceuticals expands in WA

Healthcare, minerals, energy, food: how adopting new tech could drive Australia’s economic recovery